Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Cytokine and chemokine alterations in tissue, CSF, and plasma in early presymptomatic phase of experimental allergic encephalomyelitis (EAE), in a rat model of multiple sclerosis

Fig. 1

EAE clinical profile and histopathology. a The time-course of the neurological disability score of EAE animals is reported in the graph (mean ± SD), showing the peak at day 11 (acute phase), the remission phase at day 16, and relapse at day 18. b The body weight gain in experimental animals is reported in the graph (mean ± SD), revealing a significant difference between the control and EAE group. Statistical analysis: one-way ANOVA, ****P < 0.0001. Toluidine blue staining of the lumbar spinal cord (ch) massive cellular infiltrate starting from 11 DPI (EAE t11) OX42-IR microglia staining (il). GFAP-immunostaining (mp). q The semiquantitative evaluation of the inflammation score in the LSC. r Immunoreactivity indicates that microglia activation starts at 8 DPI. s Astrocyte immunoreactivity starts at 8 DPI. Fluoromyelin staining (tw) in control (t); EAE t8 (u); EAE t11, the acute phase (v); and EAE t18, the remission-relapsing phase (w). Arrow in u indicate a partial demyelination at 8 DPI; plus in v indicates severe demyelination during the acute phase; asterisks in w indicate a partial recovery at 18 DPI. Statistical analysis: one-way ANOVA and Dunnett’s multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001). t time

Back to article page